• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

作者信息

Smith Dean, Armenteros Elena, Percy Laura, Kumar Madhu, Lach Anna, Herledan Gaelle, Stubbs Matthew, Downward Julian, Yong Kwee

机构信息

Department of Haematology, Cancer Institute, University College London, London, UK.

London Research Institute, London, UK.

出版信息

Br J Haematol. 2015 Jun;169(6):905-8. doi: 10.1111/bjh.13258. Epub 2015 Jan 12.

DOI:10.1111/bjh.13258
PMID:25580780
Abstract
摘要

相似文献

1
RAS mutation status and bortezomib therapy for relapsed multiple myeloma.RAS突变状态与硼替佐米治疗复发多发性骨髓瘤
Br J Haematol. 2015 Jun;169(6):905-8. doi: 10.1111/bjh.13258. Epub 2015 Jan 12.
2
Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.硼替佐米用于异基因造血干细胞移植后复发及移植物抗宿主病治疗多发性骨髓瘤：单中心经验
Int J Hematol. 2010 Nov;92(4):669-72. doi: 10.1007/s12185-010-0709-3. Epub 2010 Oct 27.
3
Treatment of relapsed and refractory myeloma.复发性和难治性骨髓瘤的治疗。
Curr Hematol Malig Rep. 2009 Apr;4(2):99-107. doi: 10.1007/s11899-009-0014-5.
4
Proteasome inhibitor for treatment of multiple myeloma.用于治疗多发性骨髓瘤的蛋白酶体抑制剂。
Lancet Oncol. 2005 Aug;6(8):546. doi: 10.1016/s1470-2045(05)70264-3.
5
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.复发多发性骨髓瘤患者皮下注射与静脉注射硼替佐米的比较：III期MMY-3021研究中肾功能损害患者的亚组分析
Haematologica. 2015 May;100(5):e207-10. doi: 10.3324/haematol.2014.118182. Epub 2015 Jan 16.
6
Bortezomib therapy following first relapse.首次复发后的硼替佐米治疗。
Oncology (Williston Park). 2005 Jan;19(1):23-6.
7
Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者接受基于硼替佐米的挽救治疗后的复发或进展模式。
Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):389-94. doi: 10.1016/j.clml.2014.02.004. Epub 2014 Feb 18.
8
The safety and efficacy of bortezomib in relapsed multiple myeloma.硼替佐米用于复发多发性骨髓瘤的安全性及有效性
Clin Adv Hematol Oncol. 2006 May;4(5):2-3; discussion 8; suppl 13.
9
Immortal time bias and reverse causality in retrospective analysis: Comment on "effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study".回顾性分析中的不朽时间偏倚和反向因果关系：对“III期VISTA研究中硼替佐米累积剂量对接受硼替佐米-美法仑-泼尼松治疗的多发性骨髓瘤患者生存的影响”的评论
Am J Hematol. 2015 Aug;90(8):E146. doi: 10.1002/ajh.24043. Epub 2015 May 28.
10
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.胱抑素-C是多发性骨髓瘤患者生存的独立预后因素，硼替佐米治疗可使其降低。
Haematologica. 2009 Mar;94(3):372-9. doi: 10.3324/haematol.2008.000638.

引用本文的文献

1
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma.多发性骨髓瘤髓外疾病中临床结局与分子特征的整合
Blood Cancer J. 2024 Dec 23;14(1):224. doi: 10.1038/s41408-024-01190-9.
2
Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.伴 RAS/BRAF 突变的浆细胞骨髓瘤常与复杂核型、晚期疾病和预后不良相关。
Cancer Med. 2023 Jul;12(13):14293-14304. doi: 10.1002/cam4.6103. Epub 2023 May 22.
3
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors.
多发性骨髓瘤的个性化分子治疗方法：RAF/RAS/MEK/ERK和BCL-2抑制剂的潜在应用
Explor Target Antitumor Ther. 2022;3(4):463-479. doi: 10.37349/etat.2022.00095. Epub 2022 Aug 31.
4
Pathogenic signaling in multiple myeloma.多发性骨髓瘤中的致病信号传导。
Semin Oncol. 2022 Feb;49(1):27-40. doi: 10.1053/j.seminoncol.2022.01.005. Epub 2022 Jan 20.
5
Pathway-Directed Therapy in Multiple Myeloma.多发性骨髓瘤的通路导向治疗
Cancers (Basel). 2021 Apr 1;13(7):1668. doi: 10.3390/cancers13071668.
6
, , and mutations in plasma cell myeloma at a single Korean institute.韩国某单一机构中浆细胞骨髓瘤的 、 和 突变
Blood Res. 2020 Sep 30;55(3):159-168. doi: 10.5045/br.2020.2020137.
7
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines.KRAS基因外显子4突变影响人多发性骨髓瘤细胞系中的MEK/ERK和PI3K/AKT信号通路。
Cancers (Basel). 2020 Feb 16;12(2):455. doi: 10.3390/cancers12020455.
8
Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma.在复发/难治性多发性骨髓瘤中，RAS 信号的频繁功能激活不能用 RAS/RAF 突变来解释。
Sci Rep. 2018 Sep 10;8(1):13522. doi: 10.1038/s41598-018-31820-9.
9
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?重新审视RAS合成致死筛选：仍在追寻难以捉摸的目标？
Clin Cancer Res. 2015 Apr 15;21(8):1802-9. doi: 10.1158/1078-0432.CCR-14-2180.